×
About 4,691 results

ALLMedicine™ Essential Thrombocythemia Center

Research & Reviews  2,261 results

Patients with triple-negative, JAK2V617F- and CALR-mutated essential thrombocythemia sh...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7903233
Blood Advances; Alimam S, Villiers W et. al.

Feb 18th, 2021 - Approximately 10% to 15% of patients with essential thrombocythemia (ET) lack the common driver mutations, so-called "triple-negative" (TN) disease. We undertook a systematic approach to investigate for somatic mutations and delineate gene express...

Combined venous and arterial thrombosis revealing underlying myeloproliferative disorde...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7885597
Journal of Medical Case Reports; Benmalek R, Mechal H et. al.

Feb 17th, 2021 - Myeloproliferative neoplasms (MPNs) such as polycythemia Vera (PV) and Essential Thrombocythemia (ET) can be associated with a high risk of both venous and arterial thrombosis. However, the co-existence between these two complications is very rare...

A systematic review of antithrombotic treatment of venous thromboembolism in patients w...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7805324
Blood Advances; Hamulyák EN, Daams JG et. al.

Feb 11th, 2021 - Patients with myeloproliferative neoplasms (MPNs), polycythemia vera, essential thrombocythemia, and primary myelofibrosis, have an increased risk of thrombosis. Risk of recurrent thrombosis can be reduced with antithrombotic therapy and/or cytore...

Among classic myeloproliferative neoplasms, essential thrombocythemia is associated wit...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7871138
Blood Cancer Journal; Barbui T, De Stefano V et. al.

Feb 10th, 2021 - In a multicenter European retrospective study including 162 patients with COVID-19 occurring in essential thrombocythemia (ET, n = 48), polycythemia vera (PV, n = 42), myelofibrosis (MF, n = 56), and prefibrotic myelofibrosis (pre-PMF, n = 16), 15...

Development of Alveolar Hemorrhage in a Patient with Acute Myocardial Infarction Compli...
https://doi.org/10.12659/AJCR.928409
The American Journal of Case Reports; Ishikura M, Endo A et. al.

Feb 9th, 2021 - BACKGROUND Essential thrombocythemia (ET) is a risk factor both for bleeding caused by abnormal platelet function and for thrombus formation caused by excessive platelet proliferation. We present a rare case of alveolar hemorrhage after dual antip...

see more →

Guidelines  13 results

U.S. FDA Approves INREBIC® (Fedratinib) as First New Treatment in Nearly a Decade for Patients With Myelofibrosis
https://ir.celgene.com/press-releases/press-release-details/2019/US-FDA-Approves-INREBIC-Fedratinib-as-First-New-Treatment-in-Nearly-a-Decade-for-Patients-With-Myelofibrosis/default.aspx

Aug 16th, 2019 - Celgene Corporation (NASDAQ: CELG) today announced the U.S. Food and Drug Administration (FDA) has approved INREBIC® (fedratinib) for the treatment of adult patients with intermediate-2 or high-risk primary or secondary (post-polycythemia vera or ...

NCCN Guidelines Insights: Myeloproliferative Neoplasms, Version 2.2018.
https://doi.org/10.6004/jnccn.2017.0157
Journal of the National Comprehensive Cancer Network : JN... Mesa RA, Jamieson C et. al.

Oct 6th, 2017 - Myeloproliferative neoplasms (MPNs) are a group of heterogeneous disorders of the hematopoietic system that include myelofibrosis (MF), polycythemia vera (PV), and essential thrombocythemia (ET). PV and ET are characterized by significant thromboh...

NCCN Guidelines Insights: Myeloproliferative Neoplasms, Version 2.2018
http://www.jnccn.org/content/15/10/1193.full
Mesa, R.,et al

Sep 30th, 2017 - Myeloproliferative neoplasms (MPNs) are a group of heterogeneous disorders of the hematopoietic system that include myelofibrosis (MF), polycythemia vera (PV), and essential thrombocythemia (ET). PV and ET are characterized by significant thromboh.

Myeloproliferative Neoplasms, Version 2.2017, NCCN Clinical Practice Guidelines in Onco...
https://doi.org/10.6004/jnccn.2016.0169
Journal of the National Comprehensive Cancer Network : JN... Mesa R, Jamieson C et. al.

Dec 13th, 2016 - Myelofibrosis (MF), polycythemia vera (PV), and essential thrombocythemia (ET) are a group of heterogeneous disorders of the hematopoietic system collectively known as Philadelphia chromosome-negative myeloproliferative neoplasms (MPNs). The diagn...

Myeloproliferative Neoplasms, Version 2.2017, NCCN Clinical Practice Guidelines in Oncology
http://www.jnccn.org/content/14/12/1572.full
Mesa, R.,et al

Nov 30th, 2016 - Myelofibrosis (MF), polycythemia vera (PV), and essential thrombocythemia (ET) are a group of heterogeneous disorders of the hematopoietic system collectively known as Philadelphia chromosome–negative myeloproliferative neoplasms (MPNs). The diagn.

see more →

Drugs  2 results see all →

Clinicaltrials.gov  2,329 results

Patients with triple-negative, JAK2V617F- and CALR-mutated essential thrombocythemia sh...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7903233
Blood Advances; Alimam S, Villiers W et. al.

Feb 18th, 2021 - Approximately 10% to 15% of patients with essential thrombocythemia (ET) lack the common driver mutations, so-called "triple-negative" (TN) disease. We undertook a systematic approach to investigate for somatic mutations and delineate gene express...

Combined venous and arterial thrombosis revealing underlying myeloproliferative disorde...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7885597
Journal of Medical Case Reports; Benmalek R, Mechal H et. al.

Feb 17th, 2021 - Myeloproliferative neoplasms (MPNs) such as polycythemia Vera (PV) and Essential Thrombocythemia (ET) can be associated with a high risk of both venous and arterial thrombosis. However, the co-existence between these two complications is very rare...

A systematic review of antithrombotic treatment of venous thromboembolism in patients w...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7805324
Blood Advances; Hamulyák EN, Daams JG et. al.

Feb 11th, 2021 - Patients with myeloproliferative neoplasms (MPNs), polycythemia vera, essential thrombocythemia, and primary myelofibrosis, have an increased risk of thrombosis. Risk of recurrent thrombosis can be reduced with antithrombotic therapy and/or cytore...

Among classic myeloproliferative neoplasms, essential thrombocythemia is associated wit...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7871138
Blood Cancer Journal; Barbui T, De Stefano V et. al.

Feb 10th, 2021 - In a multicenter European retrospective study including 162 patients with COVID-19 occurring in essential thrombocythemia (ET, n = 48), polycythemia vera (PV, n = 42), myelofibrosis (MF, n = 56), and prefibrotic myelofibrosis (pre-PMF, n = 16), 15...

Development of Alveolar Hemorrhage in a Patient with Acute Myocardial Infarction Compli...
https://doi.org/10.12659/AJCR.928409
The American Journal of Case Reports; Ishikura M, Endo A et. al.

Feb 9th, 2021 - BACKGROUND Essential thrombocythemia (ET) is a risk factor both for bleeding caused by abnormal platelet function and for thrombus formation caused by excessive platelet proliferation. We present a rare case of alveolar hemorrhage after dual antip...

see more →

News  71 results

U.S. FDA Approves INREBIC® (Fedratinib) as First New Treatment in Nearly a Decade for Patients With Myelofibrosis
https://ir.celgene.com/press-releases/press-release-details/2019/US-FDA-Approves-INREBIC-Fedratinib-as-First-New-Treatment-in-Nearly-a-Decade-for-Patients-With-Myelofibrosis/default.aspx

Aug 16th, 2019 - Celgene Corporation (NASDAQ: CELG) today announced the U.S. Food and Drug Administration (FDA) has approved INREBIC® (fedratinib) for the treatment of adult patients with intermediate-2 or high-risk primary or secondary (post-polycythemia vera or ...

FDA approves fedratinib for myelofibrosis
https://www.mdedge.com/hematology-oncology/article/206575/cythemias/fda-approves-fedratinib-myelofibrosis?channel=50517
Jennifer Smith

Aug 16th, 2019 - The Food and Drug Administration has approved fedratinib (Inrebic), an oral JAK2/FLT3 inhibitor, to treat myelofibrosis. Fedratinib is approved to treat adults with intermediate-2 or high-risk primary or secondary (post–polycythemia vera or post–e.

New JAK2 Inhibitor Approved for Myelofibrosis
https://www.medpagetoday.com/hematologyoncology/hematology/81650

Aug 16th, 2019 - WASHINGTON -- The FDA approved the Janus kinase 2 (JAK2) inhibitor fedratinib (Inrebic) on Friday for adults with the rare bone marrow disease myelofibrosis. Support for the approval came largely from the phase III JAKARTA study, a randomized thre...

FDA Approves Fedratinib for the Treatment of Myelofibrosis
https://www.staging.medscape.com/viewarticle/916928

Aug 15th, 2019 - The US Food and Drug Administration (FDA) has approved fedratinib (Inrebic, Celgene) capsules for the treatment of adult patients with certain types of myelofibrosis. Fedratinib, a highly selective JAK2 inhibitor, is indicated for patients with in...

FDA Approves Fedratinib for the Treatment of Myelofibrosis
https://www.medscape.com/viewarticle/916928

Aug 15th, 2019 - The US Food and Drug Administration (FDA) has approved fedratinib (Inrebic, Celgene) capsules for the treatment of adult patients with certain types of myelofibrosis. Fedratinib, a highly selective JAK2 inhibitor, is indicated for patients with in...

see more →

Patient Education  15 results see all →